Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy

Shanjuan Hong; Qing Yuan; Haizhui Xia; Genzhen Zhu; Yu Feng; Qiang Wang; Zhiyin Zhang; Wei He; Jian Lu; Chen Dong; Ling Ni

doi:10.1007/s13238-019-0642-z

Protein Cell ›› 2019, Vol. 10 ›› Issue (11) : 840 -845. DOI: 10.1007/s13238-019-0642-z

LETTER

Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy

Author information +

History +

PDF (1381KB)

Cite this article

Download citation ▾

Shanjuan Hong, Qing Yuan, Haizhui Xia, Genzhen Zhu, Yu Feng, Qiang Wang, Zhiyin Zhang, Wei He, Jian Lu, Chen Dong, Ling Ni. Analysis of VISTA expression and function in renal cell carcinoma highlights VISTA as a potential target for immunotherapy. Protein Cell, 2019, 10(11): 840-845 DOI:10.1007/s13238-019-0642-z

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Callahan MK, Postow MA, Wolchok JD (2016) Targeting T cell coreceptors for cancer therapy. Immunity 44:1069–1078

[2]	Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, Bukowski R (1992) Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1991 (11):1–11

[3]	Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O’Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS (2014) VISTA is an immune checkpoint molecule for human Tcells. Cancer Res 74:1924–1932

[4]	Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita JL, Cubas R (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554:544–548

[5]

McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, Powderly JD, Infante JR, Fasso M, Wang YV (2016) Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34:833–842

[6]	Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF(2015) Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol 33:1430–1437

[7]	Ni L, Dong C (2017a) New B7 family checkpoints in human cancers. Mol Cancer Ther 16:1203–1211

[8]	Ni L, Dong C (2017b) New checkpoints in cancer immunotherapy. Immunol Rev 276:52–65

[9]	Sittig SP, Kollgaard T, Gronbaek K, Idorn M, Hennenlotter J, Stenzl A, Gouttefangeas C, Thor Straten P (2013) Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. Oncoimmunology 2:e26014

[10]	Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C (2018) A transcriptionally and functionally distinct PD-1(+) CD8(+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 24:994–1004

[11]	Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA (2011) VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208:577–592

[12]	Xie S, Huang J, Qiao Q, Zang W, Hong S, Tan H, Dong C, Yang Z, Ni L (2018) Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. Cancer Immunol Immunother 67:1685–1694

[13]

Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, Katlinskaya Y, Kaczynski H, Conner M, Benson W (2018) Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE 13: e0206223